Lacosamide: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France), PBAC (Australia) and SMC (Scotland), among others, recommended or restricted lacosamide, while CONITEC (Brazil) did not recommend it.
The file has been open for more than a decade: 13.7 years separate the first record, 9 Feb 2009 at SMC (Scotland), from the most recent, 3 Oct 2022 at AWMSG (Wales).
AWMSG (Wales) changed its position: not recommended on 3 Apr 2017, recommended by 3 Oct 2022, after a resubmission.
No assessment is on file from CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for lacosamide, 2 submissions were never made — an outcome set by the company rather than the assessor.
7 distinct indication wordings are recorded for lacosamide by the agencies that label one in English (AWMSG, PBAC and SMC).
2 of these 22 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess lacosamide, on 9 Feb 2009; CONITEC (Brazil) did not open a file until 30 Apr 2018 — an unusually long tail of 9.2 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 11 years in total.
7 of the 7 agencies here assessed lacosamide more than once, HAS (France) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for lacosamide.
The full ledger for lacosamide reads 11 recommended, 4 not recommended, 3 other and 2 non-submission, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AWMSG (Wales) | 3 Oct 2022 | Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in children from … | recommended (licence extension for paediatric use) | source |
| PBAC (Australia) | 2021 | Epilepsy | Recommended | source |
| CONITEC (Brazil) | 30 Apr 2018 | Terapia aditiva em pacientes com epilepsia focal refratários aos tratamentos prévios com os fármacos antiepilépticos dis… | not incorporated | source |
| HAS (France) | 9 Jan 2013 | Listing (Transparency Committee) | ASMR V | source |
| PHARMAC (New Zealand) | 5 Aug 2010 | Epilepsy (third-line treatment) | PTAC advice: Decline · decision reached | source |
17 further decisions for lacosamide, across 7 agencies, are not shown here. They link to 10 further source documents.
Related molecules
- cannabidiol — same ATC class N03A — Antiepileptics
- levetiracetam — same ATC class N03A — Antiepileptics
- perampanel — same ATC class N03A — Antiepileptics
- brivaracetam — same ATC class N03A — Antiepileptics
- zonisamide — same ATC class N03A — Antiepileptics
- rufinamide — same ATC class N03A — Antiepileptics
Coverage: 22 decisions for lacosamide from 7 agencies, 2009 to 2022. Data to 7 Sep 2026. ATC class N03A — Antiepileptics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.